# TionLab Therapeutics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tionlab-therapeutics-co

- Industry: Biotechnology
- Headquarters: Yongin, South Korea
- Website: www.tionlabrx.com
- Total disclosed funding: $0.6M
- Latest round: Seed (Jul 20, 2021)
- Investors on record: 2

## About

Based in Yongin, South Korea, and founded in 2021, TionLab Therapeutics Co., Ltd., a.k.a. Tionlab Therapeutics operates as a new drug development company that focuses on developing long-lasting injections and drug delivery technology for improving the health of patients. In July 2023, TionLab Therapeutics Co., Ltd. raised an undisclosed amount of venture funding from new investor Series Ventures. As of July 2023, Duck-soo Lim is the CEO of the company. The company provides an LNP (lipid nanoparticle) platform for the delivery of various drug types, including chemicals, peptides, and RNA therapeutics. Tionlab Therapeutics also offers a microsphere platform, which is a biodegradable polymer that acts as a carrier. The firm is also developing a new drug for its next-generation drug delivery platform. The company plans to use the July 2023 funding to advance its platform technology, Quject.

## Funding rounds

- Seed, Jul 20, 2021, $0.6M — Bluepoint Partners, Daewoong Pharmaceutical

## Investors

- Bluepoint Partners (https://capitalatlas.ai/funds/bluepoint-partners) — Seed
- Daewoong Pharmaceutical — Seed